@synsci/cli-darwin-x64 1.1.97 → 1.1.99

package/bin/skills/clinical-decision-support/references/treatment_recommendations.md

@@ -1,521 +0,0 @@
-# Treatment Recommendations Guide
-
-## Overview
-
-Evidence-based treatment recommendations provide clinicians with systematic guidance for therapeutic decision-making. This guide covers the development, grading, and presentation of clinical recommendations in pharmaceutical and healthcare settings.
-
-## Evidence Grading Systems
-
-### GRADE (Grading of Recommendations Assessment, Development and Evaluation)
-
-**Quality of Evidence Levels**
-
-**High Quality (⊕⊕⊕⊕)**
-- Further research very unlikely to change confidence in estimate
-- Criteria: Well-designed RCTs with consistent results, no serious limitations
-- Example: Multiple large RCTs showing similar treatment effects
-
-**Moderate Quality (⊕⊕⊕○)**
-- Further research likely to have important impact on confidence
-- Criteria: RCTs with limitations OR very strong evidence from observational studies
-- Example: Single RCT or multiple RCTs with some inconsistency
-
-**Low Quality (⊕⊕○○)**
-- Further research very likely to have important impact on confidence
-- Criteria: Observational studies OR RCTs with serious limitations
-- Example: Case-control studies, cohort studies with confounding
-
-**Very Low Quality (⊕○○○)**
-- Estimate of effect very uncertain
-- Criteria: Case series, expert opinion, or very serious limitations
-- Example: Mechanistic reasoning, unsystematic clinical observations
-
-**Strength of Recommendation**
-
-**Strong Recommendation (Grade 1)**
-- Benefits clearly outweigh risks and burdens (or vice versa)
-- Wording: "We recommend..."
-- Implications: Most patients should receive recommended course
-- Symbol: ↑↑ (strong for) or ↓↓ (strong against)
-
-**Conditional/Weak Recommendation (Grade 2)**
-- Trade-offs exist; benefits and risks closely balanced
-- Wording: "We suggest..."
-- Implications: Different choices for different patients; shared decision-making
-- Symbol: ↑ (weak for) or ↓ (weak against)
-
-**GRADE Notation Examples**
-- **1A**: Strong recommendation, high-quality evidence
-- **1B**: Strong recommendation, moderate-quality evidence
-- **2A**: Weak recommendation, high-quality evidence
-- **2B**: Weak recommendation, moderate-quality evidence
-- **2C**: Weak recommendation, low- or very low-quality evidence
-
-### Oxford Centre for Evidence-Based Medicine (CEBM) Levels
-
-**Level 1: Systematic Review/Meta-Analysis**
-- 1a: SR of RCTs
-- 1b: Individual RCT with narrow confidence interval
-- 1c: All-or-none studies (all patients died before treatment, some survive after)
-
-**Level 2: Cohort Studies**
-- 2a: SR of cohort studies
-- 2b: Individual cohort study (including low-quality RCT)
-- 2c: Outcomes research, ecological studies
-
-**Level 3: Case-Control Studies**
-- 3a: SR of case-control studies
-- 3b: Individual case-control study
-
-**Level 4: Case Series**
-- Case series, poor-quality cohort, or case-control studies
-
-**Level 5: Expert Opinion**
-- Mechanism-based reasoning, expert opinion without critical appraisal
-
-**Grades of Recommendation**
-- **Grade A**: Consistent level 1 studies
-- **Grade B**: Consistent level 2 or 3 studies, or extrapolations from level 1
-- **Grade C**: Level 4 studies or extrapolations from level 2 or 3
-- **Grade D**: Level 5 evidence or inconsistent/inconclusive studies
-
-## Treatment Sequencing and Line-of-Therapy
-
-### First-Line Therapy
-
-**Selection Criteria**
-- **Standard of Care**: Guideline-recommended based on phase 3 trials
-- **Patient Factors**: Performance status, comorbidities, organ function
-- **Disease Factors**: Stage, molecular profile, aggressiveness
-- **Goals**: Cure (adjuvant/neoadjuvant), prolonged remission, symptom control
-
-**First-Line Options Documentation**
-```
-First-Line Treatment Options:
-
-Option 1: Regimen A (NCCN Category 1, ESMO I-A)
-- Evidence: Phase 3 RCT (n=1000), median PFS 12 months vs 8 months (HR 0.6, p<0.001)
-- Population: PD-L1 ≥50%, EGFR/ALK negative
-- Toxicity Profile: Immune-related AEs (15% grade 3-4)
-- Recommendation Strength: 1A (strong, high-quality evidence)
-
-Option 2: Regimen B (NCCN Category 1, ESMO I-A)
-- Evidence: Phase 3 RCT (n=800), median PFS 10 months vs 8 months (HR 0.7, p=0.003)
-- Population: All patients, no biomarker selection
-- Toxicity Profile: Hematologic toxicity (25% grade 3-4)
-- Recommendation Strength: 1A (strong, high-quality evidence)
-```
-
-### Second-Line and Beyond
-
-**Second-Line Selection**
-- **Prior Response**: Duration of response to first-line
-- **Progression Pattern**: Oligoprogression vs widespread progression
-- **Residual Toxicity**: Recovery from first-line toxicities
-- **Biomarker Evolution**: Acquired resistance mechanisms
-- **Clinical Trial Availability**: Novel agents in development
-
-**Treatment History Documentation**
-```
-Prior Therapies:
-1. First-Line: Pembrolizumab (12 cycles)
-   - Best Response: Partial response (-45% tumor burden)
-   - PFS: 14 months
-   - Discontinuation Reason: Progressive disease
-   - Residual Toxicity: Grade 1 hypothyroidism (on levothyroxine)
-
-2. Second-Line: Docetaxel + ramucirumab (6 cycles)
-   - Best Response: Stable disease
-   - PFS: 5 months  
-   - Discontinuation Reason: Progressive disease
-   - Residual Toxicity: Grade 2 peripheral neuropathy
-
-Current Consideration: Third-Line Options
-- Clinical trial vs platinum-based chemotherapy
-```
-
-### Maintenance Therapy
-
-**Indications**
-- Consolidation after response to induction therapy
-- Prevention of progression without continuous cytotoxic treatment
-- Bridging to definitive therapy (e.g., transplant)
-
-**Evidence Requirements**
-- PFS benefit demonstrated in randomized trials
-- Tolerable long-term toxicity profile
-- Quality of life preserved or improved
-
-## Biomarker-Guided Therapy Selection
-
-### Companion Diagnostics
-
-**FDA-Approved Biomarker-Drug Pairs**
-
-**Required Testing (Treatment-Specific)**
-- **ALK rearrangement → Alectinib, Brigatinib, Lorlatinib** (NSCLC)
-- **EGFR exon 19 del/L858R → Osimertinib** (NSCLC)
-- **BRAF V600E → Dabrafenib + Trametinib** (Melanoma, NSCLC, CRC)
-- **HER2 amplification/3+ → Trastuzumab, Pertuzumab** (Breast, Gastric)
-- **PD-L1 ≥50% → Pembrolizumab monotherapy** (NSCLC first-line)
-
-**Complementary Diagnostics (Informative but not Required)**
-- **PD-L1 1-49%**: Combination immunotherapy preferred
-- **TMB-high**: May predict immunotherapy benefit (investigational)
-- **MSI-H/dMMR**: Pembrolizumab approved across tumor types
-
-### Biomarker Testing Algorithms
-
-**NSCLC Biomarker Panel**
-```
-Reflex Testing at Diagnosis:
-✓ EGFR mutations (exons 18, 19, 20, 21)
-✓ ALK rearrangement (IHC or FISH)
-✓ ROS1 rearrangement (FISH or NGS)
-✓ BRAF V600E mutation
-✓ PD-L1 IHC (22C3 or SP263)
-✓ Consider: Comprehensive NGS panel
-
-If EGFR+ on Osimertinib progression:
-✓ Liquid biopsy for T790M (if first/second-gen TKI)
-✓ Tissue biopsy for resistance mechanisms
-✓ MET amplification, HER2 amplification, SCLC transformation
-```
-
-**Breast Cancer Biomarker Algorithm**
-```
-Initial Diagnosis:
-✓ ER/PR IHC
-✓ HER2 IHC and FISH (if 2+)
-✓ Ki-67 proliferation index
-
-If Metastatic ER+/HER2-:
-✓ ESR1 mutations (liquid biopsy after progression on AI)
-✓ PIK3CA mutations (for alpelisib eligibility)
-✓ BRCA1/2 germline testing (for PARP inhibitor eligibility)
-✓ PD-L1 testing (if considering immunotherapy combinations)
-```
-
-### Actionable Alterations
-
-**Tier I: FDA-Approved Targeted Therapy**
-- Strong evidence from prospective trials
-- Guideline-recommended
-- Examples: EGFR exon 19 deletion, HER2 amplification, ALK fusion
-
-**Tier II: Clinical Trial or Off-Label Use**
-- Emerging evidence, clinical trial preferred
-- Examples: NTRK fusion (larotrectinib), RET fusion (selpercatinib)
-
-**Tier III: Biological Plausibility**
-- Preclinical evidence only
-- Clinical trial enrollment strongly recommended
-- Examples: Novel kinase fusions, rare resistance mutations
-
-## Combination Therapy Protocols
-
-### Rationale for Combinations
-
-**Mechanisms**
-- **Non-Overlapping Toxicity**: Maximize dose intensity of each agent
-- **Synergistic Activity**: Enhanced efficacy beyond additive effects
-- **Complementary Mechanisms**: Target multiple pathways simultaneously
-- **Prevent Resistance**: Decrease selection pressure for resistant clones
-
-**Combination Design Principles**
-- **Sequential**: Induction then consolidation (different regimens)
-- **Concurrent**: Administered together for synergy
-- **Alternating**: Rotate regimens to minimize resistance
-- **Intermittent**: Pulse dosing vs continuous exposure
-
-### Drug Interaction Assessment
-
-**Pharmacokinetic Interactions**
-- **CYP450 Induction/Inhibition**: Check for drug-drug interactions
-- **Transporter Interactions**: P-gp, BCRP, OATP substrates/inhibitors
-- **Protein Binding**: Highly protein-bound drugs (warfarin caution)
-- **Renal/Hepatic Clearance**: Avoid multiple renally cleared agents
-
-**Pharmacodynamic Interactions**
-- **Additive Toxicity**: Avoid overlapping adverse events (e.g., QTc prolongation)
-- **Antagonism**: Ensure mechanisms are complementary, not opposing
-- **Dose Modifications**: Pre-defined dose reduction schedules for combinations
-
-### Combination Documentation
-
-```
-Combination Regimen: Drug A + Drug B
-
-Rationale:
-- Phase 3 RCT demonstrated PFS benefit (16 vs 11 months, HR 0.62, p<0.001)
-- Complementary mechanisms: Drug A (VEGF inhibitor) + Drug B (immune checkpoint inhibitor)
-- Non-overlapping toxicity profiles
-
-Dosing:
-- Drug A: 10 mg/kg IV every 3 weeks
-- Drug B: 1200 mg IV every 3 weeks
-- Continue until progression or unacceptable toxicity
-
-Key Toxicities:
-- Hypertension (Drug A): 30% grade 3-4, manage with antihypertensives
-- Immune-related AEs (Drug B): 15% grade 3-4, corticosteroid management
-- No significant pharmacokinetic interactions observed
-
-Monitoring:
-- Blood pressure: Daily for first month, then weekly
-- Thyroid function: Every 6 weeks  
-- Liver enzymes: Before each cycle
-- Imaging: Every 6 weeks (RECIST v1.1)
-```
-
-## Monitoring and Follow-up Schedules
-
-### On-Treatment Monitoring
-
-**Laboratory Monitoring**
-```
-Test                   Baseline  Cycle 1  Cycle 2+  Rationale
-CBC with differential  ✓         Weekly   Day 1     Myelosuppression risk
-Comprehensive panel    ✓         Day 1    Day 1     Electrolytes, renal, hepatic
-Thyroid function       ✓         -        Q6 weeks  Immunotherapy
-Lipase/amylase        ✓         -        As needed Pancreatitis risk
-Troponin/BNP          ✓*        -        As needed Cardiotoxicity risk
-(*if cardiotoxic agent)
-```
-
-**Imaging Assessment**
-```
-Modality           Baseline  Follow-up           Criteria
-CT chest/abd/pelvis ✓       Every 6-9 weeks     RECIST v1.1
-Brain MRI          ✓*       Every 12 weeks      If CNS metastases
-Bone scan          ✓**      Every 12-24 weeks   If bone metastases
-PET/CT             ✓***     Response assessment Lymphoma (Lugano criteria)
-(*if CNS mets, **if bone mets, ***if PET-avid tumor)
-```
-
-**Clinical Assessment**
-```
-Assessment               Frequency                Notes
-ECOG performance status  Every visit              Decline may warrant dose modification
-Vital signs              Every visit              Blood pressure for anti-VEGF agents
-Weight                   Every visit              Cachexia, fluid retention
-Symptom assessment       Every visit              PRO-CTCAE questionnaire
-Physical exam            Every visit              Target lesions, new symptoms
-```
-
-### Dose Modification Guidelines
-
-**Hematologic Toxicity**
-```
-ANC and Platelet Counts          Action
-ANC ≥1.5 AND platelets ≥100k    Treat at full dose
-ANC 1.0-1.5 OR platelets 75-100k Delay 1 week, recheck
-ANC 0.5-1.0 OR platelets 50-75k  Delay treatment, G-CSF support, reduce dose 20%
-ANC <0.5 OR platelets <50k       Hold treatment, G-CSF, transfusion PRN, reduce 40%
-
-Febrile Neutropenia              Hold treatment, hospitalize, antibiotics, G-CSF
-                                Reduce dose 20-40% on recovery, consider prophylactic G-CSF
-```
-
-**Non-Hematologic Toxicity**
-```
-Adverse Event     Grade 1         Grade 2              Grade 3              Grade 4
-Diarrhea          Continue        Continue with        Hold until ≤G1,      Hold, hospitalize
-                                 loperamide           reduce 20%           Consider discontinuation
-Rash              Continue        Continue with        Hold until ≤G1,      Discontinue
-                                 topical Rx           reduce 20%
-Hepatotoxicity    Continue        Repeat in 1 wk,      Hold until ≤G1,      Discontinue permanently
-                                 hold if worsening    reduce 20-40%
-Pneumonitis       Continue        Hold, consider       Hold, corticosteroids, Discontinue, high-dose
-                                 corticosteroids      discontinue if no improvement steroids
-```
-
-### Post-Treatment Surveillance
-
-**Disease Monitoring**
-```
-Time After Treatment    Imaging Frequency        Labs                   Clinical
-Year 1                  Every 3 months          Every 3 months         Every 3 months
-Year 2                  Every 3-4 months        Every 3-4 months       Every 3-4 months
-Years 3-5               Every 6 months          Every 6 months         Every 6 months
-Year 5+                 Annually               Annually               Annually
-
-Earlier imaging if symptoms suggest recurrence
-```
-
-**Survivorship Care**
-```
-Surveillance              Frequency                     Duration
-Disease monitoring        Per schedule above            Lifelong or until recurrence
-Late toxicity screening   Annually                      Lifelong
-  - Cardiac function     Every 1-2 years               If anthracycline/trastuzumab
-  - Pulmonary function   As clinically indicated        If bleomycin/radiation
-  - Neuropathy           Symptom-based                  Peripheral neuropathy history
-  - Secondary malignancy Age-appropriate screening       Lifelong (increased risk)
-Genetic counseling        One time                      If hereditary cancer syndrome
-Psychosocial support     As needed                      Depression, anxiety, PTSD screening
-```
-
-## Special Populations
-
-### Elderly Patients (≥65-70 years)
-
-**Considerations**
-- **Reduced organ function**: Adjust for renal/hepatic impairment
-- **Polypharmacy**: Drug-drug interaction risk
-- **Frailty**: Geriatric assessment (G8, VES-13, CARG score)
-- **Goals of care**: Quality of life vs survival, functional independence
-
-**Modifications**
-- Dose reductions: 20-25% reduction for frail patients
-- Longer intervals: Every 4 weeks instead of every 3 weeks
-- Less aggressive regimens: Single-agent vs combination therapy
-- Supportive care: Increased monitoring, G-CSF prophylaxis
-
-### Renal Impairment
-
-**Dose Adjustments by eGFR**
-```
-eGFR (mL/min/1.73m²)    Category  Action
-≥90                     Normal    Standard dosing
-60-89                   Mild      Standard dosing (most agents)
-30-59                   Moderate  Dose reduce renally cleared drugs 25-50%
-15-29                   Severe    Dose reduce 50-75%, avoid nephrotoxic agents
-<15 (dialysis)          ESRD      Avoid most agents, case-by-case decisions
-```
-
-**Renally Cleared Agents Requiring Adjustment**
-- Carboplatin (Calvert formula: AUC × [GFR + 25])
-- Methotrexate (reduce dose 50-75% if CrCl <60)
-- Capecitabine (reduce dose 25-50% if CrCl 30-50)
-
-### Hepatic Impairment
-
-**Dose Adjustments by Bili and AST/ALT**
-```
-Category          Bilirubin         AST/ALT        Action
-Normal           ≤ULN              ≤ULN           Standard dosing
-Mild (Child A)    1-1.5× ULN        Any            Reduce dose 25% for hepatically metabolized
-Moderate (Child B) 1.5-3× ULN       Any            Reduce dose 50%, consider alternative
-Severe (Child C)  >3× ULN           Any            Avoid most agents, case-by-case
-```
-
-**Hepatically Metabolized Agents Requiring Adjustment**
-- Docetaxel (reduce 25-50% if bilirubin elevated)
-- Irinotecan (reduce 50% if bilirubin 1.5-3× ULN)
-- Tyrosine kinase inhibitors (most metabolized by CYP3A4, reduce by 50%)
-
-### Pregnancy and Fertility
-
-**Contraception Requirements**
-- Effective contraception required during treatment and 6-12 months after
-- Two methods recommended for highly teratogenic agents
-- Male patients: Contraception if partner of childbearing potential
-
-**Fertility Preservation**
-- Oocyte/embryo cryopreservation (females, before gonadotoxic therapy)
-- Sperm banking (males, before alkylating agents, platinum)
-- GnRH agonists (ovarian suppression, controversial efficacy)
-- Referral to reproductive endocrinology before treatment
-
-**Pregnancy Management**
-- Avoid chemotherapy in first trimester (organogenesis)
-- Selective agents safe in second/third trimester (case-by-case)
-- Multidisciplinary team: oncology, maternal-fetal medicine, neonatology
-
-## Clinical Trial Considerations
-
-### When to Recommend Clinical Trials
-
-**Ideal Scenarios**
-- No standard therapy available (rare diseases, refractory settings)
-- Multiple equivalent standard options (patient preference for novel agent)
-- Standard therapy failed (second-line and beyond)
-- High-risk disease (adjuvant trials for improved outcomes)
-
-**Trial Selection Criteria**
-- **Phase**: Phase 1 (dose-finding, safety), Phase 2 (efficacy signal), Phase 3 (comparative effectiveness)
-- **Eligibility**: Match patient to inclusion/exclusion criteria
-- **Mechanism**: Novel vs established mechanism, biological rationale
-- **Sponsor**: Academic vs industry, trial design quality
-- **Logistics**: Distance to trial site, visit frequency, out-of-pocket costs
-
-### Shared Decision-Making
-
-**Informing Patients**
-- Natural history without treatment
-- Standard treatment options with evidence, benefits, risks
-- Clinical trial options (if available)
-- Goals of care alignment
-- Patient values and preferences
-
-**Decision Aids**
-- Visual representations of benefit (icon arrays)
-- Number needed to treat calculations
-- Quality of life trade-offs
-- Decisional conflict scales
-
-## Documentation Standards
-
-### Treatment Plan Documentation
-
-```
-TREATMENT PLAN
-
-Diagnosis: [Disease, stage, molecular profile]
-
-Goals of Therapy:
-☐ Curative intent
-☐ Prolonged disease control
-☑ Palliation and quality of life
-
-Recommended Regimen: [Name] (NCCN Category 1, GRADE 1A)
-
-Evidence Basis:
-- Primary study: [Citation], Phase 3 RCT, n=XXX
-- Primary endpoint: PFS 12 months vs 8 months (HR 0.6, 95% CI 0.45-0.80, p<0.001)
-- Secondary endpoints: OS 24 vs 20 months (HR 0.75, p=0.02), ORR 60% vs 40%
-- Safety: Grade 3-4 AEs 35%, discontinuation rate 12%
-
-Dosing Schedule:
-- Drug A: XX mg IV day 1
-- Drug B: XX mg PO days 1-21
-- Cycle length: 21 days
-- Planned cycles: Until progression or unacceptable toxicity
-
-Premedications:
-- Dexamethasone 8 mg IV (anti-emetic)
-- Ondansetron 16 mg IV (anti-emetic)
-- Diphenhydramine 25 mg IV (hypersensitivity prophylaxis)
-
-Monitoring Plan: [See schedule above]
-
-Dose Modification Plan: [See guidelines above]
-
-Alternative Options Discussed:
-- Option 2: [Alternative regimen], GRADE 1B
-- Clinical trial: [Trial name/number], Phase 2, novel agent
-- Best supportive care
-
-Patient Decision: Proceed with recommended regimen
-
-Informed Consent: Obtained for chemotherapy, risks/benefits discussed
-
-Date: [Date]
-Provider: [Name, credentials]
-```
-
-## Quality Metrics
-
-### Treatment Recommendation Quality Indicators
-
-- Evidence grading provided for all recommendations
-- Multiple options presented when equivalent evidence exists
-- Toxicity profiles clearly described
-- Monitoring plans specified
-- Dose modification guidelines included
-- Special populations addressed (elderly, renal/hepatic impairment)
-- Clinical trial options mentioned when appropriate
-- Shared decision-making documented
-- Goals of care aligned with treatment intensity
-